Laniquidar
Laniquidar (INN) is a P-glycoprotein inhibitor undergoing clinical studies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).[1]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C37H36N4O3 |
Molar mass | 584.70 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
References
- Ross DD (2004). "Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome". Best practice & research. Clinical haematology. 17 (4): 641–51. doi:10.1016/j.beha.2004.08.014. PMID 15494300.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.